590782388	590782388	CD	B-NP	O
|	|	NN	I-NP	O
OH	OH	NN	I-NP	O
|	|	NN	I-NP	O
87702030	87702030	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
4145081	4145081	CD	B-NP	O
|	|	CC	I-NP	O
10/21/2005	10/21/2005	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
right	right	JJ	I-NP	O
MCA	MCA	NNP	I-NP	O
stroke	stroke	VBD	B-VP	O
|	|	NNP	B-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
10/21/2005	10/21/2005	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Discharge	Discharge	NNP	B-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
6/18/2005	6/18/2005	CD	B-NP	O
******	******	SYM	I-NP	O
FINAL	FINAL	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
ORDERS	ORDERS	NN	I-NP	O
******	******	SYM	B-VP	O
TREVETHAN	TREVETHAN	NN	B-NP	O
,	,	,	O	O
JERALD	JERALD	NN	B-NP	O
185-13-97-9	185-13-97-9	CD	I-NP	O
Ville	Ville	NNP	I-NP	O
Service	Service	NNP	I-NP	O
:	:	:	O	O
NEU	NEU	NNP	B-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
PATIENT	PATIENT	NNP	I-NP	O
ON	ON	NNP	I-NP	O
:	:	:	O	O
9/19/05	9/19/05	CD	B-NP	O
AT	AT	NN	I-NP	O
02	02	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
PM	PM	NNP	I-NP	O
CONTINGENT	CONTINGENT	NNP	I-NP	O
UPON	UPON	NNP	I-NP	O
Not	Not	NNP	I-NP	O
Applicable	Applicable	NNP	I-NP	O
WILL	WILL	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
ORDER	ORDER	NNP	I-NP	O
BE	BE	NNP	I-NP	O
USED	USED	NNP	I-NP	O
AS	AS	NNP	I-NP	O
THE	THE	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
SUMMARY	SUMMARY	NNP	I-NP	O
:	:	:	O	O
YES	YES	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
BRANSCUM	BRANSCUM	NNP	B-NP	O
,	,	,	O	O
BRENTON	BRENTON	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
CODE	CODE	NNP	I-NP	O
STATUS	STATUS	NNP	I-NP	O
:	:	:	O	O
Full	Full	JJ	B-NP	O
code	code	NN	I-NP	O
DISPOSITION	DISPOSITION	NN	I-NP	O
:	:	:	O	O
Rehabilitation	Rehabilitation	NN	B-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
CIPROFLOXACIN	CIPROFLOXACIN	NN	B-NP	B-protein
500	500	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
Q12H	Q12H	NN	I-NP	I-protein
X	X	SYM	B-NP	I-protein
10	10	CD	B-NP	I-protein
doses	dose	NNS	I-NP	I-protein
Food/Drug	Food/Drug	NNP	B-NP	I-protein
Interaction	Interaction	NNP	I-NP	I-protein
Instruction	Instruction	NNP	I-NP	I-protein
Administer	Administer	NNP	I-NP	I-protein
iron	iron	NN	I-NP	I-protein
products	product	NNS	I-NP	I-protein
a	a	DT	B-NP	O
minimum	minimum	NN	I-NP	O
of	of	IN	B-PP	O
2	2	CD	B-NP	O
hours	hour	NNS	I-NP	O
before	before	IN	B-PP	O
or	or	CC	I-PP	O
after	after	IN	I-PP	O
a	a	DT	B-NP	O
levofloxacin	levofloxacin	NN	I-NP	O
or	or	CC	I-NP	O
ciprofloxacin	ciprofloxacin	NN	I-NP	O
dose	dose	NN	I-NP	O
dose	dose	NN	I-NP	O
If	If	IN	B-SBAR	O
on	on	IN	B-PP	O
tube	tube	NN	B-NP	O
feeds	feed	NNS	I-NP	O
,	,	,	O	O
please	please	VB	B-VP	O
cycle	cycle	NN	B-NP	B-protein
-LRB-	-LRB-	NN	I-NP	I-protein
hold	hold	VBP	B-VP	O
1	1	CD	B-NP	O
hr	hr	NN	I-NP	O
before	before	IN	B-PP	O
to	to	TO	B-PP	O
2	2	CD	B-NP	O
hr	hr	NN	I-NP	O
after	after	IN	B-PP	O
-RRB-	-RRB-	NN	B-NP	B-protein
Take	Take	NN	I-NP	I-protein
2	2	CD	B-NP	I-protein
hours	hour	NNS	I-NP	I-protein
before	before	IN	B-PP	O
or	or	CC	B-NP	O
2	2	CD	I-NP	O
hours	hour	NNS	I-NP	O
after	after	IN	B-PP	O
dairy	dairy	NN	B-NP	O
products	product	NNS	I-NP	O
.	.	.	O	O

DEXTROAMPHETAMINE	DEXTROAMPHETAMINE	NN	B-NP	O
SULFATE	SULFATE	NN	I-NP	O
10	10	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
QD	QD	NN	I-NP	O
COLACE	COLACE	NN	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
DOCUSATE	DOCUSATE	NNP	I-NP	O
SODIUM	SODIUM	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
100	100	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
INSULIN	INSULIN	NNP	I-NP	O
REGULAR	REGULAR	NNP	I-NP	O
HUMAN	HUMAN	NNP	I-NP	O
Sliding	Sliding	NNP	I-NP	O
Scale	Scale	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
subcutaneously	subcutaneously	RB	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
SC	SC	NN	I-NP	B-protein
TID	TID	NN	I-NP	I-protein
If	If	IN	B-SBAR	I-protein
BS	BS	NNP	B-NP	I-protein
is	be	VBZ	B-VP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
125	125	CD	I-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
0	0	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
125-150	125-150	CD	B-NP	O
,	,	,	O	O
then	then	RB	O	O
give	give	VB	B-VP	O
2	2	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
151-200	151-200	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
3	3	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
201-250	201-250	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
4	4	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
251-300	251-300	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
6	6	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
301-350	301-350	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
8	8	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
If	If	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
351-400	351-400	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
10	10	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
and	and	CC	O	O
call	call	VB	B-VP	O
HO	HO	NN	B-NP	B-protein
Call	Call	NN	I-NP	I-protein
HO	HO	NN	I-NP	I-protein
if	if	IN	B-SBAR	O
BS	BS	NNP	B-NP	O
is	be	VBZ	B-VP	O
greater	great	JJR	B-NP	O
than	than	IN	I-NP	O
400	400	CD	I-NP	O
LEVOTHYROXINE	LEVOTHYROXINE	NN	I-NP	O
SODIUM	SODIUM	NN	I-NP	O
125	125	CD	I-NP	O
MCG	MCG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QD	QD	NNP	I-NP	O
ATIVAN	ATIVAN	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
LORAZEPAM	LORAZEPAM	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
0.5	0.5	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
Q4H	Q4H	NN	I-NP	O
PRN	PRN	NN	I-NP	O
Anxiety	Anxiety	NN	I-NP	O
METOPROLOL	METOPROLOL	NN	I-NP	O
TARTRATE	TARTRATE	NN	I-NP	O
12.5	12.5	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
BID	BID	NN	I-NP	O
HOLD	HOLD	NN	I-NP	O
IF	IF	NN	I-NP	O
:	:	:	O	O
SBP	SBP	NN	B-NP	B-protein
<	<	SYM	O	O
120	120	CD	B-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Take	Take	NNP	I-NP	O
consistently	consistently	RB	B-ADVP	O
with	with	IN	B-PP	O
meals	meal	NNS	B-NP	O
or	or	CC	B-PP	O
on	on	IN	B-PP	O
empty	empty	JJ	B-NP	O
stomach	stomach	NN	I-NP	O
.	.	.	O	O

SENNA	SENNA	NN	B-NP	O
TABLETS	TABLETS	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
SENNOSIDES	SENNOSIDES	NN	I-NP	B-DNA
-RRB-	-RRB-	HYPH	B-NP	I-DNA
2	2	CD	I-NP	I-DNA
TAB	TAB	NN	I-NP	I-DNA
PO	PO	NN	I-NP	I-DNA
BID	BID	NN	I-NP	I-DNA
SIMVASTATIN	SIMVASTATIN	NN	I-NP	I-DNA
20	20	CD	I-NP	I-DNA
MG	MG	NNP	I-NP	I-DNA
PO	PO	NNP	I-NP	I-DNA
QHS	QHS	NNP	I-NP	I-DNA
Food/Drug	Food/Drug	NNP	I-NP	I-DNA
Interaction	Interaction	NNP	I-NP	I-DNA
Instruction	Instruction	NNP	I-NP	I-DNA
Avoid	Avoid	NNP	I-NP	I-DNA
grapefruit	grapefruit	NN	I-NP	I-DNA
unless	unless	IN	B-SBAR	I-DNA
MD	MD	NN	B-NP	I-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

REMERON	REMERON	NN	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
MIRTAZAPINE	MIRTAZAPINE	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
7.5	7.5	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QHS	QHS	NNP	I-NP	O
Number	Number	NNP	I-NP	O
of	of	IN	B-PP	O
Doses	Doses	NNP	B-NP	O
Required	Required	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
approximate	approximate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
5	5	CD	B-NP	O
LAMICTAL	LAMICTAL	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
LAMOTRIGINE	LAMOTRIGINE	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
200	200	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
Number	Number	NNP	I-NP	O
of	of	IN	B-PP	O
Doses	Doses	NNP	B-NP	O
Required	Required	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
approximate	approximate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
5	5	CD	B-NP	O
CLOPIDOGREL	CLOPIDOGREL	NN	I-NP	O
75	75	CD	B-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QD	QD	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
Today	Today	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
11/24	11/24	CD	I-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
HOLD	HOLD	NN	I-NP	B-protein
IF	IF	NN	I-NP	I-protein
:	:	:	O	O
plt	plt	NN	B-NP	O
count	count	NN	I-NP	O
<	<	SYM	O	O
100	100	CD	B-NP	O
DUONEB	DUONEB	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ALBUTEROL	ALBUTEROL	NN	I-NP	O
AND	AND	CC	I-NP	O
IPRATROPIUM	IPRATROPIUM	NN	I-NP	O
NEBULIZER	NEBULIZER	NN	I-NP	O
-RRB-	-RRB-	SYM	B-NP	O
3/0	3/0	CD	I-NP	O
.5	.5	CD	I-NP	O
MG	MG	NN	I-NP	O
NEB	NEB	NN	I-NP	O
Q6H	Q6H	NN	I-NP	O
PRN	PRN	NN	I-NP	O
Shortness	Shortness	NN	I-NP	O
of	of	IN	B-PP	O
Breath	Breath	NNP	B-NP	O
NIASPAN	NIASPAN	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
NICOTINIC	NICOTINIC	NNP	I-NP	O
ACID	ACID	NNP	I-NP	O
SUSTAINED	SUSTAINED	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
0.5	0.5	CD	I-NP	O
GM	GM	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QHS	QHS	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
Today	Today	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
11/24	11/24	CD	I-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
HOLD	HOLD	NN	I-NP	B-protein
IF	IF	NN	I-NP	I-protein
:	:	:	O	O
myalgias	myalgia	NNS	B-NP	O
Alert	Alert	NNP	B-NP	O
overridden	overridden	JJ	B-ADJP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
9/19/05	9/19/05	CD	B-NP	O
by	by	IN	B-PP	O
:	:	:	O	O
POTENTIALLY	POTENTIALLY	NNP	B-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
SIMVASTATIN	SIMVASTATIN	NNP	B-NP	O
&	&	CC	I-NP	O
NIACIN	NIACIN	NNP	I-NP	O
,	,	,	O	O
VIT	VIT	NNP	B-NP	O
.	.	.	O	O

B-3	B-3	NN	B-NP	B-protein
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
will	will	MD	B-VP	O
monitor	monitor	VB	I-VP	O
SALT	SALT	NN	B-NP	B-protein
TABLET	TABLET	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
SODIUM	SODIUM	NN	I-NP	I-protein
CHLORIDE	CHLORIDE	NN	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
1	1	CD	I-NP	I-protein
GM	GM	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
BID	BID	NNP	I-NP	O
DIET	DIET	NNP	I-NP	O
:	:	:	O	O
Mechanical	Mechanical	NNP	B-NP	O
Soft/Thin	Soft/Thin	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
no	no	DT	B-NP	O
consistency	consistency	NN	I-NP	O
restriction	restriction	NN	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
FDI	FDI	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
DIET	DIET	NNP	I-NP	O
:	:	:	O	O
House	House	NNP	B-NP	O
/	/	SYM	B-NP	O
Low	Low	JJ	I-NP	O
chol/low	chol/low	NN	I-NP	O
sat	sat	NN	I-NP	O
.	.	.	O	O

fat	fat	JJ	B-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
House	House	NN	B-NP	O
/	/	SYM	O	O
ADA	ADA	NN	B-NP	O
2100	2100	CD	I-NP	O
cals/dy	cals/dy	NN	I-NP	O
RETURN	RETURN	NNP	I-NP	O
TO	TO	NNP	I-NP	O
WORK	WORK	NNP	I-NP	O
:	:	:	O	O
Not	Not	NNP	B-NP	O
Applicable	Applicable	NNP	I-NP	O
FOLLOW	FOLLOW	NNP	I-NP	O
UP	UP	NNP	I-NP	O
APPOINTMENT	APPOINTMENT	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
S	S	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
Dr.	Dr.	NNP	B-NP	O
Hegg	Hegg	NNP	I-NP	O
,	,	,	O	O
MHS	MHS	NNP	B-NP	O
622-840-9570	622-840-9570	CD	B-NP	O
2	2	CD	I-NP	O
weeks	week	NNS	I-NP	O
,	,	,	O	O
PCP	PCP	NN	B-NP	B-protein
Dr.	Dr.	NNP	I-NP	I-protein
Babiracki	Babiracki	NNP	I-NP	I-protein
547-466-8501	547-466-8501	CD	I-NP	I-protein
3-4	3-4	CD	I-NP	I-protein
weeks	week	NNS	I-NP	I-protein
,	,	,	O	O
Neurologist	Neurologist	NNP	B-NP	O
Dr.	Dr.	NNP	I-NP	O
Stencil	Stencil	NNP	I-NP	O
ASAP	ASAP	NNP	I-NP	O
,	,	,	O	O
Oncologist	Oncologist	NNP	B-NP	O
Dr.	Dr.	NNP	I-NP	O
Calvello	Calvello	NNP	I-NP	O
as	as	IN	B-SBAR	O
previously	previously	RB	B-ADVP	O
determined	determine	VBN	B-VP	O
,	,	,	O	O
ALLERGY	ALLERGY	NNP	B-NP	O
:	:	:	O	O
Demerol	Demerol	NNP	B-NP	O
,	,	,	O	O
Penicillins	Penicillins	NNP	B-NP	O
,	,	,	O	O
Codeine	Codeine	NNP	B-NP	O
,	,	,	O	O
Sulfa	Sulfa	NNP	B-NP	O
,	,	,	O	O
IV	IV	NNP	B-NP	O
Contrast	Contrast	NNP	I-NP	O
,	,	,	O	O
LEVETIRACETAM	LEVETIRACETAM	NNP	B-NP	O
,	,	,	O	O
DIVALPROEX	DIVALPROEX	NNP	B-NP	O
SODIUM	SODIUM	NNP	I-NP	O
ADMIT	ADMIT	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
:	:	:	O	O
stroke	stroke	VB	B-VP	O
PRINCIPAL	PRINCIPAL	NNP	B-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
;	;	:	O	O
Responsible	Responsible	JJ	B-ADJP	O
After	After	IN	B-PP	O
Study	Study	NNP	B-NP	O
for	for	IN	B-PP	O
Causing	Causing	NNP	B-NP	O
Admission	Admission	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
right	right	JJ	I-NP	O
MCA	MCA	NNP	I-NP	O
stroke	stroke	VBD	B-VP	O
OTHER	OTHER	NNP	B-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
;	;	:	O	O
Conditions	Condition	NNS	B-NP	O
,	,	,	O	O
Infections	Infection	NNS	B-NP	O
,	,	,	O	O
Complications	Complication	NNS	B-NP	O
,	,	,	O	O
affecting	affect	VBG	B-VP	O
Treatment/Stay	Treatment/Stay	NNP	B-NP	O
severe	severe	JJ	I-NP	O
right	right	JJ	I-NP	O
internal	internal	JJ	I-NP	O
carotid	carotid	NN	I-NP	O
artery	artery	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
non-small	non-small	JJ	I-NP	O
cell	cell	NN	I-NP	O
lung	lung	NN	I-NP	O
cancer	cancer	NN	I-NP	O
,	,	,	O	O
pancytopenia	pancytopenia	NN	B-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
chemotherapy	chemotherapy	NN	B-NP	O
hypertension	hypertension	NN	I-NP	O
,	,	,	O	O
dyslipidemia	dyslipidemia	NN	B-NP	O
,	,	,	O	O
type	type	NN	B-NP	O
2	2	CD	I-NP	O
diabetes	diabetes	NN	I-NP	O
mellitus	mellitus	NN	I-NP	O
epilepsy	epilepsy	NN	I-NP	O
chronic	chronic	JJ	I-NP	O
obstructive	obstructive	JJ	I-NP	O
pulmonary	pulmonary	JJ	I-NP	O
disease	disease	NN	I-NP	O
hypothyroidism	hypothyroidism	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
post-Graves	post-Grave	NNS	I-NP	O
'	'	POS	B-NP	O
disease	disease	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
SIADH	SIADH	NN	I-NP	O
OPERATIONS	OPERATIONS	NNS	I-NP	O
AND	AND	CC	I-NP	O
PROCEDURES	PROCEDURES	NNS	I-NP	O
:	:	:	O	O
OTHER	OTHER	NNP	B-NP	O
TREATMENTS/PROCEDURES	TREATMENTS/PROCEDURES	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
NOT	NOT	NNP	I-NP	O
IN	IN	NNP	I-NP	O
O.R.	O.R.	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
MRI/MRA	MRI/MRA	NNP	I-NP	O
head	head	NN	I-NP	O
and	and	CC	I-NP	O
neck	neck	NN	I-NP	O
CT/CTA	CT/CTA	NN	I-NP	O
head	head	NN	I-NP	O
and	and	CC	O	O
neck	neck	NN	B-NP	O
noncontrast	noncontrast	NN	I-NP	O
head	head	NN	I-NP	O
CT	CT	NN	I-NP	O
x	x	SYM	O	O
4	4	CD	B-NP	O
video	video	NN	I-NP	O
swallowing	swallow	VBG	B-VP	O
study	study	NN	B-NP	O
transthoracic	transthoracic	JJ	I-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
BRIEF	BRIEF	NN	I-NP	O
RESUME	RESUME	NN	I-NP	O
OF	OF	IN	B-PP	O
HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
64	64	CD	I-NP	O
year-old	year-old	JJ	I-NP	O
right-handed	right-handed	JJ	I-NP	O
woman	woman	NN	I-NP	O
presented	present	VBD	B-VP	O
after	after	IN	B-PP	O
being	be	VBG	B-VP	O
found	find	VBN	I-VP	O
down	down	IN	B-PP	O
and	and	CC	O	O
weak	weak	JJ	B-ADJP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
left	left	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
recent	recent	JJ	I-NP	O
diagnosis	diagnosis	NN	I-NP	O
of	of	IN	B-PP	O
non-small	non-small	JJ	B-NP	O
cell	cell	NN	I-NP	O
lung	lung	NN	I-NP	O
cancer	cancer	NN	I-NP	O
and	and	CC	O	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
receiving	receive	VBG	I-VP	O
chemotherapy	chemotherapy	NN	B-NP	O
and	and	CC	I-NP	O
radiation	radiation	NN	I-NP	O
therapy	therapy	NN	I-NP	O
treatments	treatment	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
presented	present	VBD	B-VP	O
outside	outside	IN	B-PP	O
the	the	DT	B-NP	O
window	window	NN	I-NP	O
for	for	IN	B-PP	O
thrombolysis	thrombolysis	NN	B-NP	O
or	or	CC	I-NP	O
intervention	intervention	NN	I-NP	O
.	.	.	O	O

Exam	Exam	NN	B-NP	O
revealed	reveal	VBD	B-VP	O
plegia	plegia	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
face	face	NN	I-NP	O
and	and	CC	I-NP	O
arm	arm	NN	I-NP	O
,	,	,	O	O
paresis	paresis	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
leg	leg	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
an	an	DT	B-NP	O
incomplete	incomplete	JJ	I-NP	O
neglect	neglect	NN	I-NP	O
syndrome	syndrome	NN	I-NP	O
.	.	.	O	O

MRI/MRA	MRI/MRA	NN	B-NP	O
revealed	reveal	VBD	B-VP	O
partial	partial	JJ	B-NP	O
right	right	JJ	I-NP	O
MCA	MCA	NNP	I-NP	O
territory	territory	NN	I-NP	O
stroke	stroke	VBD	B-VP	O
and	and	CC	I-VP	O
suggested	suggest	VBD	I-VP	O
severe	severe	JJ	B-NP	O
proximal	proximal	JJ	I-NP	O
right	right	JJ	I-NP	O
ICA	ICA	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
;	;	:	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
heparin	heparin	NN	B-NP	O
.	.	.	O	O

Antihypertensives	Antihypertensive	NNS	B-NP	O
,	,	,	O	O
aside	aside	RB	B-ADVP	O
from	from	IN	B-PP	O
low-dose	low-dose	JJ	B-NP	O
metoprolol	metoprolol	NN	I-NP	O
,	,	,	O	O
were	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
.	.	.	O	O

CT/CTA	CT/CTA	NN	B-NP	O
head	head	NN	I-NP	O
and	and	CC	O	O
neck	neck	NN	B-NP	O
the	the	DT	B-NP	O
following	follow	VBG	I-NP	O
day	day	NN	I-NP	O
confirmed	confirm	VBD	B-VP	O
a	a	DT	B-NP	O
severe	severe	JJ	I-NP	O
proximal	proximal	JJ	I-NP	O
right	right	JJ	I-NP	O
ICA	ICA	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
and	and	CC	O	O
revealed	reveal	VBD	B-VP	O
evolution	evolution	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
stroke	stroke	NN	I-NP	O
to	to	TO	B-VP	O
involve	involve	VB	I-VP	O
much	much	JJ	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
MCA	MCA	NNP	I-NP	O
territory	territory	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
heparin	heparin	NN	I-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
placed	place	VBN	B-VP	O
back	back	RB	B-ADVP	O
on	on	IN	B-PP	O
clopidogrel	clopidogrel	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
Hoaggan	Hoaggan	NNP	I-NP	O
Memorial	Memorial	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
under	under	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Aiu	Aiu	NNP	I-NP	O
evaluated	evaluate	VBD	B-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
and	and	CC	O	O
recommended	recommend	VBD	B-VP	O
a	a	DT	B-NP	O
follow-up	follow-up	JJ	I-NP	O
appointment	appointment	NN	I-NP	O
with	with	IN	B-PP	O
him	him	PRP	B-NP	O
two	two	CD	B-NP	O
weeks	week	NNS	I-NP	O
after	after	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

Laboratory	Laboratory	NN	B-NP	O
work-up	work-up	NN	I-NP	O
pertinent	pertinent	JJ	B-ADJP	O
to	to	TO	B-VP	O
stroke	stroke	VB	I-VP	O
revealed	reveal	VBD	B-VP	O
a	a	DT	B-NP	O
normal	normal	JJ	I-NP	O
homocysteine	homocysteine	NN	I-NP	O
,	,	,	O	O
normal	normal	JJ	B-NP	O
TSH	TSH	NN	I-NP	O
,	,	,	O	O
lipid	lipid	NN	B-NP	O
profile	profile	NN	I-NP	O
with	with	IN	B-PP	O
LDL	LDL	NN	B-NP	B-protein
108	108	CD	I-NP	I-protein
,	,	,	O	O
HDL	HDL	NN	B-NP	B-DNA
52	52	CD	I-NP	I-DNA
,	,	,	O	O
TG	TG	NN	B-NP	O
131	131	CD	I-NP	O
,	,	,	O	O
and	and	CC	O	O
Lp	Lp	NN	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
a	a	DT	B-NP	O
-RRB-	-RRB-	NN	I-NP	B-protein
lipoprotein	lipoprotein	NN	I-NP	I-protein
elevated	elevate	VBD	B-VP	O
at	at	IN	B-PP	O
93	93	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
statin	statin	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
low-dose	low-dose	JJ	B-NP	O
niacin	niacin	NN	I-NP	O
added	add	VBN	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
regimen	regimen	NN	I-NP	O
because	because	IN	B-PP	O
of	of	IN	I-PP	O
the	the	DT	B-NP	O
Lp	Lp	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
a	a	DT	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
results	result	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
hemoglobin	hemoglobin	NN	I-NP	B-protein
A1c	A1c	NN	I-NP	O
and	and	CC	O	O
random	random	JJ	B-NP	B-protein
blood	blood	NN	I-NP	I-protein
sugars	sugar	NNS	I-NP	I-protein
were	be	VBD	B-VP	O
elevated	elevate	VBN	I-VP	O
;	;	:	O	O
she	she	PRP	B-NP	O
received	receive	VBD	B-VP	O
an	an	DT	B-NP	O
insulin	insulin	NN	I-NP	B-protein
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
.	.	.	O	O

Echocardiogram	Echocardiogram	NN	B-NP	O
showed	show	VBD	B-VP	O
normal	normal	JJ	B-NP	O
LVEF	LVEF	NN	I-NP	B-protein
and	and	CC	I-NP	O
size	size	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
wall	wall	NN	I-NP	O
motion	motion	NN	I-NP	O
abnormalities	abnormality	NNS	I-NP	O
,	,	,	O	O
+	+	JJ	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
diastolic	diastolic	JJ	B-NP	O
dysfunction	dysfunction	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
normal	normal	JJ	B-NP	O
LA	LA	NN	I-NP	O
size	size	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
cell	cell	NN	I-NP	O
counts	count	NNS	I-NP	O
trended	trend	VBD	B-VP	O
downward	downward	RB	B-ADVP	O
in	in	IN	B-PP	O
an	an	DT	B-NP	O
expected	expected	JJ	I-NP	O
fashion	fashion	NN	I-NP	O
given	give	VBN	B-PP	O
the	the	DT	B-NP	O
timing	timing	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
most	most	RBS	I-NP	O
recent	recent	JJ	I-NP	O
chemotherapy	chemotherapy	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
neutropenic	neutropenic	JJ	B-NP	O
precautions	precaution	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
oncologist	oncologist	NN	I-NP	O
Dr.	Dr.	NNP	I-NP	O
Batrez	Batrez	NNP	I-NP	O
recommended	recommend	VBD	B-VP	O
administering	administer	VBG	I-VP	O
prophylactic	prophylactic	JJ	B-NP	O
ciprofloxacin	ciprofloxacin	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
single	single	JJ	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
long-acting	long-acting	JJ	B-NP	O
G-CSF	G-CSF	NN	I-NP	B-protein
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
not	not	RB	I-VP	O
planned	plan	VBN	I-VP	O
to	to	TO	I-VP	O
receive	receive	VB	I-VP	O
any	any	DT	B-NP	O
additional	additional	JJ	I-NP	O
chemotherapeutic	chemotherapeutic	NN	I-NP	O
or	or	CC	I-NP	O
radiation	radiation	NN	I-NP	O
therapy	therapy	NN	I-NP	O
treatments	treatment	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
near	near	JJ	I-NP	O
future	future	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
neurological	neurological	JJ	I-NP	O
examination	examination	NN	I-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
.	.	.	O	O

Repeat	Repeat	NN	B-NP	O
head	head	NN	I-NP	O
CTs	CT	NNS	I-NP	O
done	do	VBN	B-VP	O
to	to	TO	B-VP	O
assess	assess	VB	I-VP	O
for	for	IN	B-PP	O
edema	edema	NN	B-NP	O
following	follow	VBG	B-PP	O
the	the	DT	B-NP	O
stroke	stroke	NN	I-NP	O
revealed	reveal	VBD	B-VP	O
some	some	DT	B-NP	O
effacement	effacement	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
lateral	lateral	JJ	I-NP	O
ventricle	ventricle	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
no	no	DT	B-NP	O
threatening	threatening	JJ	I-NP	O
mass	mass	NN	I-NP	O
effect	effect	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
serum	serum	NN	I-NP	O
sodium	sodium	NN	I-NP	O
trended	trend	VBD	B-VP	O
down	down	RB	B-ADVP	O
throughout	throughout	IN	B-PP	O
admission	admission	NN	B-NP	O
;	;	:	O	O
it	it	PRP	B-NP	O
is	be	VBZ	B-VP	O
recommended	recommend	VBN	I-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
not	not	RB	O	O
receive	receive	VBP	B-VP	O
hypotonic	hypotonic	JJ	B-NP	O
fluids	fluid	NNS	I-NP	O
at	at	IN	B-PP	O
rehab	rehab	NN	B-NP	O
and	and	CC	O	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
be	be	VB	B-VP	O
water	water	NN	B-NP	O
restricted	restricted	JJ	B-ADJP	O
to	to	TO	B-PP	O
1L	1L	NN	B-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
take	take	VB	B-VP	O
salt	salt	NN	B-NP	O
as	as	IN	B-SBAR	O
directed	direct	VBN	B-VP	O
.	.	.	O	O

Given	Give	VBN	B-PP	O
her	her	PRP$	B-NP	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
is	be	VBZ	B-VP	O
recommended	recommend	VBN	I-VP	O
that	that	IN	B-SBAR	O
antiplatelet	antiplatelet	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
with	with	IN	B-PP	O
clopidogrel	clopidogrel	NN	B-NP	O
be	be	VB	B-VP	O
held	hold	VBN	I-VP	O
until	until	IN	B-PP	O
her	her	PRP$	B-NP	O
platelet	platelet	NN	I-NP	O
count	count	NN	I-NP	O
rises	rise	VBZ	B-VP	O
over	over	IN	B-PP	O
100	100	CD	B-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
is	be	VBZ	B-VP	O
also	also	RB	I-VP	O
recommended	recommend	VBN	I-VP	O
that	that	IN	B-SBAR	O
anticoagulation	anticoagulation	NN	B-NP	O
with	with	IN	B-PP	O
therapeutic	therapeutic	JJ	B-NP	O
low-molecular	low-molecular	JJ	I-NP	O
weight	weight	NN	I-NP	O
heparin	heparin	NN	I-NP	O
as	as	IN	B-PP	O
bridge	bridge	NN	B-NP	O
to	to	TO	B-PP	O
warfarin	warfarin	NN	B-NP	O
with	with	IN	B-PP	O
target	target	NN	B-NP	O
INR	INR	NN	I-NP	O
2-3	2-3	CD	I-NP	O
be	be	VB	B-VP	O
restarted	restart	VBN	I-VP	O
2	2	CD	B-NP	O
weeks	week	NNS	I-NP	O
after	after	IN	B-PP	O
her	her	PRP$	B-NP	O
stroke	stroke	NN	I-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
2/16/05	2/16/05	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
should	should	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
for	for	IN	B-PP	O
neurological	neurological	JJ	B-NP	O
issues	issue	NNS	I-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Sagan	Sagan	NNP	I-NP	O
of	of	IN	B-PP	O
neurosurgery	neurosurgery	NN	B-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
her	her	PRP$	B-NP	O
outpatient	outpatient	NN	I-NP	O
neurologist	neurologist	NN	I-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Collin	Collin	NNP	I-NP	O
Krauskopf	Krauskopf	NNP	I-NP	O
,	,	,	O	O
at	at	IN	B-PP	O
Cako	Cako	NNP	B-NP	O
Hospital	Hospital	NNP	I-NP	O
ADDITIONAL	ADDITIONAL	NNP	I-NP	O
COMMENTS	COMMENTS	NNP	I-NP	O
:	:	:	O	O
DISCHARGE	DISCHARGE	NN	B-NP	O
CONDITION	CONDITION	NN	I-NP	O
:	:	:	O	O
Fair	Fair	NNP	B-NP	O
TO	TO	NNP	I-NP	O
DO/PLAN	DO/PLAN	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

hold	hold	VB	B-VP	O
clopidogrel	clopidogrel	NN	B-NP	O
until	until	IN	B-PP	O
plt	plt	NN	B-NP	B-protein
>	>	SYM	O	I-protein
100k	100k	CD	B-NP	I-protein
2	2	CD	I-NP	I-protein
.	.	.	O	O

start	start	VB	B-VP	O
low-molecular	low-molecular	JJ	B-NP	B-protein
weight	weight	NN	I-NP	I-protein
heparin	heparin	NN	I-NP	I-protein
as	as	IN	B-PP	O
a	a	DT	B-NP	O
bridge	bridge	NN	I-NP	O
to	to	TO	B-PP	O
warfarin	warfarin	NN	B-NP	O
-LRB-	-LRB-	HYPH	I-NP	O
target	target	NN	I-NP	O
INR	INR	NN	I-NP	O
2-3	2-3	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
and	and	CC	O	O
discontinue	discontinue	NN	B-NP	O
clopidogrel	clopidogrel	NN	I-NP	O
7/1/05	7/1/05	CD	B-NP	O
3	3	CD	I-NP	O
.	.	.	O	O

Free	Free	JJ	B-NP	O
water	water	NN	I-NP	O
restrict	restrict	NN	I-NP	O
1L	1L	NN	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
,	,	,	O	O
follow	follow	VBP	B-VP	O
serum	serum	NN	B-NP	O
sodium	sodium	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Follow	Follow	VB	B-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Amoah	Amoah	NNP	I-NP	O
in	in	IN	B-PP	O
2	2	CD	B-NP	O
weeks	week	NNS	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
dictated	dictated	JJ	I-NP	O
summary	summary	NN	I-NP	O
ENTERED	ENTERED	NNP	I-NP	O
BY	BY	NNP	I-NP	O
:	:	:	O	O
NAPOLITANO	NAPOLITANO	NNP	B-NP	O
,	,	,	O	O
CLINT	CLINT	NNP	B-NP	O
RAY	RAY	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
IQ99	IQ99	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
9/19/05	9/19/05	CD	I-NP	O
@	@	SYM	B-NP	O
02	02	CD	I-NP	O
******	******	SYM	I-NP	O
END	END	NN	I-NP	O
OF	OF	IN	B-PP	O
DISCHARGE	DISCHARGE	NN	B-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	B-NP	O

